April 1, 2022
Detaching from the mothership?
It’s really not a secret that Medtronic isn’t thrilled with how things are going in diabetes. Yes, publicly they say all is well and things will get better but privately they acknowledge this unit is in a world of hurt. As we have reported in the past management has considered several options – selling to private equity – combining the diabetes unit with another unit and then spinning off this new entity as a separate publicly traded company and finally keeping diabetes.
Our sources indicate that exiting diabetes is the preferred option however the problem is one of valuation combined . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
